Nanyanyiso Baloi holds her treatment regimen for pre-XDR-TB.
Drug-resistant TB

TAC and MSF intervene in a case for a lifesaving cystic fibrosis drug priced at over R5 million

In what could be a ground-breaking case for affordable access to medicines in South Africa, the Treatment Action Campaign (TAC) and Doctors Without Borders (MSF) Southern Africa, both represented by SECTION27, have filed papers in the Pretoria High Court to intervene as amici curiae (friends of the court) in a compulsory licence application for access to a lifesaving drug to treat cystic fibrosis, called Trikafta.

Cystic fibrosis is a severe multisystem illness that can cause frequent serious lung infections, including antimicrobial-resistant bacteria, liver and pancreatic damage, and lung failure, and can even necessitate a lung transplant.

Cheri Nel, a South African patient with cystic fibrosis has brought a case against Vertex Pharmaceuticals Inc, an American pharmaceutical company that patented Trikafta, an effective new drug that changes the trajectory and impact of cystic fibrosis for patients diagnosed with the illness. The drug is however priced at an impossible amount of US $311,000 per year per patient in America (approximately R5,722,400). Given that cystic fibrosis is a chronic condition, patients are required to take this drug for the rest of their lives.  

MSF fieldworker speaking with a DR-TB patient
Phenduka Mtshali, a patient with Drug Resistant Tuberculosis (DR-TB), is seen at her home in Mbongolwane, South Africa speaking with MSF fieldworker, Jabulile. Phenduka lives in Mbongolwane a rural area of South Africa’s KwaZulu-Natal province at the epicentre of South Africa’s HIV & TB epidemic and where MSF is currently piloting a model of care aimed at upgrading the TB treatment cascade.
MSF/Tadeu Andre

With their wealth of experience in access to medicines on a domestic and international level, in their application for intervention, TAC and MSF seek to make legal submissions on the broader context of access to medicines in South Africa. As organisations that were at the forefront of fighting for lifesaving HIV medicines that were unaffordable for most people living with HIV in the early 2000s, TAC and MSF also seek to introduce evidence on the recent international developments in intellectual property, particularly on access to treatments for drug-resistance tuberculosis (DR-TB), Hepatitis C virus, and COVID-19 medicines and vaccines amid the pandemic. This evidence will place into context the role of compulsory licencing as a mechanism to expand access to medicines.

“MSF has dealt first-hand with the frustration and impact of intellectual property protection on access to medicines in the delivery of care to patients," - Candice Sehoma, MSF Advocacy Advisor.

“MSF has dealt first-hand with the frustration and impact of intellectual property protection on access to medicines in the delivery of care to patients. To this end, South Africa’s patent law remains unreformed, making our fight for access even more difficult and cyclical despite the historical nature of the issue spanning from the formidable fight to access ARVs. We have had to fight similar challenges in the struggle to access lifesaving medicines for other life-threatening diseases. And the struggle is further made difficult because pharmaceutical corporate powers are more entrenched in our public health system and are now more globalised than ever before,” says Candice Sehoma, MSF Advocacy Advisor. 

The application seeks to make legal submissions on how the denial of access to medicines, occasioned by monopolies due to patent protections, can infringe the constitutional right to access health care services, which includes the right to access medicines. In this regard, TAC and MSF’s submissions provide guidance to the Court on how to interpret the Patents Act 57 of 1978 in a manner consistent with the Constitution and international law, including binding human rights covenants and the WTO Agreement in Trade-related Aspects of Intellectual Property (TRIPS Agreement).

TAC and MSF’s evidence and legal submissions are significant to the determination of the main application. This is because they demonstrate how compulsory licences are a legal mechanism to enable access to medicines. The main applicants, as well as Vertex, have granted consent for TAC and MSF to be admitted as friends of the court. 

View court papers by TAC and MSF pdf — 543.91 KB

Download View online